Armata Pharmaceuticals, Inc. (NYSE American:ARMP) reported Tuesday that shareholders elected seven directors and approved key proposals at the company’s annual meeting held Thursday last week, according to a press release statement based on a recent SEC filing.
At the meeting, shareholders voted to elect Deborah L. Birx, M.D., Daniel B. Gilmer, Ph.D., Jules Haimovitz, Odysseas D. Kostas, M.D., Robin C. Kramer, Joseph M. Patti, Ph.D., and Sarah Schlesinger, M.D. Each director will serve a one-year term until the 2027 annual meeting. Vote totals for each nominee ranged from 28,349,266 to 28,544,094 shares in favor, with between 48,142 and 242,970 shares withheld. There were 1,257,467 broker non-votes for each nominee.The governance vote comes as Armata’s stock trades at $6.79, down 11% over the past week, though shares have surged 276% over the past year. The company carries a market capitalization of $253.56 million.
Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. The vote recorded 28,547,283 shares in favor, 27,765 shares against, 17,188 shares abstaining, and 1,257,467 broker non-votes.
In a separate advisory vote, shareholders indicated a preference for holding future advisory votes on executive compensation annually. The results showed 28,567,809 shares for a one-year frequency, 2,400 shares for two years, 17,113 shares for three years, 4,914 shares abstaining, and 1,257,467 broker non-votes. Following this outcome, Armata’s board determined that the company will continue to hold advisory votes on executive compensation every year until the next required frequency vote or until the board decides otherwise.
Additionally, shareholders ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 29,842,514 shares in favor, 6,631 shares against, and 558 shares abstaining, with no broker non-votes.
All information is based on a press release statement and details disclosed in the company’s recent SEC filing.
In other recent news, Armata Pharmaceuticals reported fourth-quarter results that did not meet analyst expectations. The company announced an adjusted earnings per share of -$3.42, significantly below the consensus estimate of -$0.19. Revenue for the quarter was $1.1 million, which also fell short of the anticipated $1.48 million. Additionally, Armata Pharmaceuticals received Fast Track Designation from the U.S. Food and Drug Administration for its intravenous multi-phage product candidate, AP-SA02, intended to treat complicated bacteremia. This designation allows for more frequent FDA engagement and could lead to Accelerated Approval and Priority Review. In governance updates, Armata Pharmaceuticals welcomed Daniel B. Gilmer, Ph.D., a Pfizer executive, to its Board of Directors. Furthermore, the company has scheduled its 2026 annual meeting of stockholders for June 11, 2026. Stockholders of record as of April 17, 2026, will be eligible to participate in the meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates ARMP alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ARMP is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?